These factors include the use of dulaglutide or semaglutide, age, gender, hypertension, CKD, dyslipidemia, baseline HbA1c, and serum low-density lipoprotein cholesterol (LDL), and the use of SGLT2 inhibitors, angiotensin II receptor blockers (ARBs), biguanides, and statins. This evidence concerns the gene SLC5A2 and chronic kidney disease.